v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in millions): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Xywav$471.2 $415.3 $879.4 $760.1 
Xyrem30.5 35.4 61.7 72.6 
Sleep501.7 450.7 941.1 832.7 
Epidiolex/Epidyolex292.1 251.7 541.9 469.4 
Epilepsy292.1 251.7 541.9 469.4 
Zepzelca105.8 74.5 206.8 137.5 
Rylaze/Enrylaze99.5 100.7 203.2 194.9 
Defitelio/defibrotide 62.0 48.1 109.4 88.8 
Modeyso48.2 0.5 89.6 0.5 
Vyxeos31.4 44.9 58.0 74.4 
Ziihera15.4 6.0 28.7 8.0 
Oncology362.3 274.7 695.7 504.1 
Other1
— 8.5 2.7 18.8 
Product sales, net1,156.1 985.6 2,181.4 1,825.0 
High-sodium oxybate AG royalty revenue42.2 54.1 78.5 103.0 
Other royalty and contract revenues10.0 6.0 17.3 15.5 
Total revenues$1,208.3 $1,045.7 $2,277.2 $1,943.5 
____________________________
(1) Includes Sativex net product sales for the three and six months ended June 30, 2025.
The following table presents a summary of total revenues attributed to geographic sources (in millions): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
U.S.$1,077.9 $936.3 $2,037.7 $1,734.8 
Europe97.4 82.7 189.8 165.7 
All other33.0 26.7 49.7 43.0 
Total revenues$1,208.3 $1,045.7 $2,277.2 $1,943.5 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
ESSDS41 %43 %41 %42 %
McKesson11 %10 %11 %11 %
ASD10 %11 %11 %11 %
The percentage of trade receivables by customers who individually accounted for 10% or more of our trade receivables were as follows: 
June 30,
2026		December 31,
2025
ESSDS41 %41 %
ASD15 %16 %
McKesson13 %11 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days.